News

New Study Shows HIFU for Prostate Cancer Yields Excellent Cancer Control

New 5-Year Sonablate® Study Shows Focal HIFU for Prostate Cancer Yields Excellent Cancer Control with Minimal Side Effects HIFU Prostate Services, the largest provider of HIFU Services in US is pleased to announce an Extensive Multicenter Research Study that Demonstrates Sonablate® HIFU Outcomes are Equivalent to Surgery While Maintaining Urinary Continence and Erectile Function Charlotte, N.C. (July 6, 2018) – A 5-year multicenter study following focal therapy for prostate cancer, with the Sonablate HIFU technology, has been published and shows it is possible to achieve whole-gland equivalent cancer control rates without the side effects seen with whole gland treatments. The data demonstrated that focal Sonablate HIFU, or High Intensity Focused Ultrasound, has achieved success rates similar to more traditional prostate cancer surgical procedures [...]

2018-07-17T10:08:41+00:00July 17th, 2018|

New Study: HIFU for prostate cancer as effective as surgery or radiotherapy

Using high energy ultrasound beams to destroy prostate cancer tumors may be as effective as surgery or radiotherapy, but with fewer side effects. A new study, carried out at six hospitals across the UK, tracked 625 men with prostate cancer who received a type of treatment called high-intensity focused ultrasound (HIFU). The research, published in the journal European Urology, is the largest ever study of HIFU treatment used to target prostate tumours. The treatment is similar to a 'lumpectomy' for other cancers -- where doctors remove only tumour cells, leaving as much healthy tissue as possible. The findings, from a number of institutions including Imperial College London and University College London, found that after five years the cancer survival rate from HIFU was 100 per [...]

2018-07-10T08:20:41+00:00July 10th, 2018|

Global health insurance company Cigna covers HIFU

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center --> Cigna, a a global health insurance service company based in the US, announced earlier this year that patients in the United States who have localized radio-recurrent prostate cancer are potentially eligible for insurance coverage for HIFU treatment. In other words, if a man was diagnosed with localized prostate cancer and then had radiation therapy then had the cancer return to the prostate and was diagnosed with localized recurrent prostate cancer, he may be eligible for coverage for having HIFU as a salvage option. It is important to note that coverage is policy specific so it may vary depending on the policy.  More information is available from Cigna [...]

2018-06-19T14:59:20+00:00June 19th, 2018|

It’s Men’s Health Month – A Focus on Prostate Cancer Prevention

Is prostate cancer prevention possible? Urologist and prostate cancer specialist Dr. Michael Lazar talks about prevention and options for maintaining health after a cancer diagnosis. June is Men’s Health Month and the focus is on prostate cancer. Second only to skin cancer, prostate cancer is the most common cancer among men in the U.S. and the third most common cause of cancer related death today; lung cancer remains in the number one spot. Currently it is estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk are men who have a family history of prostate cancer and black men, who are more than twice as likely to die from the disease as any other group. [...]

2018-06-12T07:40:41+00:00June 12th, 2018|

New study reviews PSA screening results following prostate cancer treatment

A study assessed whether monitoring prostate cancer patients following treatment with a PSA test every three months versus once a year would provide a long-term survival benefit. Prostate cancer patients who were monitored more frequently after treatment did not live significantly longer than patients who were monitored once a year, according to study findings led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher. At the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, researchers presented findings on Friday, June 1, from an analysis of data from nearly 10,500 prostate cancer patients in the United States from 2005 to 2010. The study's primary goal was to determine if more frequent monitoring with the prostate-specific antigen test after treatment improved patients' [...]

2018-06-05T11:03:37+00:00June 5th, 2018|

Fewer men are being screened, diagnosed, and treated for prostate cancer

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]

2018-05-22T15:07:32+00:00May 22nd, 2018|

Who is the best candidate for HIFU prostate cancer treatment?

Is HIFU Prostate Cancer Treatment for You? High Intensity Focused Ultrasound (HIFU) is a FDA approved non-invasive therapy for treating prostate cancer. Find out if you qualify for HIFU. HIFU may not be appropriate in every situation, but it is most effective for men who have early stage, localized prostate cancer that has not spread or metastasized outside the prostate HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. At the focal point of the sound waves (like a magnifying glass focusing the rays of [...]

2018-05-08T08:30:04+00:00May 8th, 2018|

New biopsy technology may identify better course of treatment for prostate cancer

Prostate cancer is the second most common cancer in men and the fifth leading cause of death from cancer in men worldwide, according to 2012 numbers. While several viable treatment options for prostate cancer exist, many men affected with prostate cancer will not respond to first-line treatments. Researchers in the Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto have developed a new technology for liquid biopsy to identify which patients may not respond to standard therapy before it is delivered. "Screening for drug resistance is key to improving treatment approaches for many cancers," said Shana Kelley, scientist and professor at the Leslie Dan Faculty of Pharmacy, University of Toronto. "It's important for patients not to be on a [...]

2018-04-24T10:27:34+00:00April 24th, 2018|

Random PSA screening misses some aggressive and lethal prostate cancers

UK researchers say that inviting men with no symptoms to a one-off PSA test for prostate cancer does not save lives. This from the largest ever prostate cancer trial conducted over 10 years by Cancer Research UK-funded scientists and published in the Journal of the American Medical Association (JAMA). Researchers at the Universities of Bristol and Oxford found that testing asymptomatic men with PSA detects some disease that would be unlikely to cause any harm but also misses some aggressive and lethal prostate cancers. This highlights the flaws of a single PSA test as a way to screen for prostate cancer, and shows the need to find more accurate ways to diagnose cancers that need to be treated. The CAP Trial, which spanned almost [...]

2018-03-13T10:59:50+00:00March 13th, 2018|

New PET scan targets copper in tumors to detect prostate cancer

An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level). Copper tends to be more concentrated in tumors, making it a good imaging biomarker. For this study of 50 patients, researchers conducted PET/CT scans comparing the new imaging agent, copper-64 chloride (64CuCl2), with fluorine-18-choline (18F-Choline). Multiparametric magnetic resonance imaging (mpMRI) was also conducted. In addition to calculating the detection rate of each imaging modality, the biodistribution, kinetics of the lesions and radiation dosimetry of 64CuCl2 were evaluated. "This is the first time this novel agent has been compared with 18F-Choline-PET/CT in a considerable number of prostate [...]

2018-03-06T07:35:43+00:00March 6th, 2018|